Biosignal Ltd
Suite 145, Level 1
National Innovation Centre
Australian Technology Park
EVELEIGH NSW 1430
Telephone +61 2 9209 4126
Facsimile +61 2 9209 4306
ACN 071 781 363
ABN 45 071 781 363

ASX Announcement

Dr Michael Ironside New Head of Chemistry at Biosignal

29 May 2007, Sydney: Dr Michael Ironside has been named Head of Chemistry at Biosignal (ASX: BOS) and will oversee the company's anti-bacterial development projects. Dr Ironside, who will be based in Sydney, has over fifteen years experience gained in the biotech and pharmaceutical sectors of both the US and Europe. He joins Biosignal after nine years in senior managerial roles with AMRI Global (AMRI), a major chemistry-based drug discovery, development and manufacturing company based in Albany, New York. His most recent position at AMRI was Vice President of Chemical Development/Small Scale GMP, where he managed the company's scientific staff, based in the USA and India, involved in progressing novel active pharmaceutical ingredients (APIs) along the development spectrum from lead identification through clinical trials to commercial reality.

"Mike's extensive experience in synthetic chemistry including technology transfer, GMP pharmaceutical manufacturing and commercial production makes him one of the best qualified in this field in Australia," said Michael Oredsson, Managing Director and CEO of Biosignal.

Prior to joining AMRI, Dr Ironside was a scientific manager at Hovione, Portugal where he led teams developing synthetic processes for APIs for use in clinical trials.

Dr Ironside holds a Ph.D. in organic chemistry from Dundee University in Scotland and was a postdoctoral fellow at Sydney University.

Inquiries: Michael Oredsson
02 9209 4106
m.oredsson@biosignal.com.au

Rudi Michelson
Monsoon Communications
0411 402 737
rudim@monsoon.com.au

About Biosignal and the anti-biofilm technology

Biosignal listed on the ASX in April 2004 to commercialise a novel anti-bacterial technology. The first applications are reducing risks of infection from contact lenses and as anti-corrosive agents in oil & gas infrastructure.

Biosignal's anti-biofilm technology is based on a discovery that the eastern Australian seaweed *Delisea pulchra* produces natural furanones that disable bacteria's ability to colonise. The fundamental problem with existing anti-bacterials, including antibiotics, is bacterial resistance. Bacteria rapidly produce

resistant strains when faced with strong selective pressure by killing agents or growth-inhibitory agents. Furanones lull bacteria to inaction and appear to avoid the problem of bacterial resistance.

Biosignal produces synthetic compounds effective on inanimate surfaces such as pipes and membranes and animate surfaces such as lungs, skin and teeth. Biosignal's collaborations with US, European and Japanese companies are assessing new applications across a range of consumer and industrial products.